secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2025-05-20T23:59:59+00:00
Accession:  0001641172-25-011607
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Q1 net loss narrows to $4.7M, cuts costs, eyes Nebula sale, $50M recovery
--------------------------------------------------------------------------------

- Q1 net revenue $1.4M (down from $2.4M YoY); net loss $4.7M ($0.13/shr) vs $5.5M loss ($0.32/shr) last year.
- Headcount slashed from 96 to 25; Pharmaloz divested for ~$23M, genomics lab closed, saving >$6M annually.
- Engaged ThinkEquity to sell Nebula Genomics; 16-petabyte DNA dataset; sale expected within 3-4 months.
- Crown Medical expects ~$50M in insurance recoveries; company carries $20M A/R for this initiative.
- BE-Smart esophageal test submitted for peer review; LDT rule vacated by federal judge on Apr 1, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000164117225011607/0001641172-25-011607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000164117225011607/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-011607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer